RU2017137262A - Применение (4-гидрокси-2-метил-1,1-диоксид-2н-бензо[е][1,2]тиазин-3-ил)(нафталин-2-ил)метанона для профилактики и/или лечения неалкогольного стеатогепатита - Google Patents
Применение (4-гидрокси-2-метил-1,1-диоксид-2н-бензо[е][1,2]тиазин-3-ил)(нафталин-2-ил)метанона для профилактики и/или лечения неалкогольного стеатогепатита Download PDFInfo
- Publication number
- RU2017137262A RU2017137262A RU2017137262A RU2017137262A RU2017137262A RU 2017137262 A RU2017137262 A RU 2017137262A RU 2017137262 A RU2017137262 A RU 2017137262A RU 2017137262 A RU2017137262 A RU 2017137262A RU 2017137262 A RU2017137262 A RU 2017137262A
- Authority
- RU
- Russia
- Prior art keywords
- benzo
- hydroxy
- dioxide
- methyl
- treatment
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 title 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 claims 5
- -1 [1,2] thiazin-3-yl Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 159000000001 potassium salts Chemical class 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1553574 | 2015-04-21 | ||
| FR1553574A FR3035326B1 (fr) | 2015-04-21 | 2015-04-21 | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
| PCT/EP2016/058760 WO2016169983A1 (fr) | 2015-04-21 | 2016-04-20 | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017137262A true RU2017137262A (ru) | 2019-05-21 |
| RU2017137262A3 RU2017137262A3 (enExample) | 2019-09-30 |
Family
ID=53484018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017137262A RU2017137262A (ru) | 2015-04-21 | 2016-04-20 | Применение (4-гидрокси-2-метил-1,1-диоксид-2н-бензо[е][1,2]тиазин-3-ил)(нафталин-2-ил)метанона для профилактики и/или лечения неалкогольного стеатогепатита |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180140609A1 (enExample) |
| EP (1) | EP3285774B1 (enExample) |
| JP (1) | JP2018513175A (enExample) |
| KR (1) | KR20170139030A (enExample) |
| CN (1) | CN107530355A (enExample) |
| AU (1) | AU2016251601A1 (enExample) |
| BR (1) | BR112017021586A2 (enExample) |
| CA (1) | CA2981933A1 (enExample) |
| FR (1) | FR3035326B1 (enExample) |
| MX (1) | MX2017013453A (enExample) |
| RU (1) | RU2017137262A (enExample) |
| WO (1) | WO2016169983A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102177304B1 (ko) | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| RU2706026C1 (ru) * | 2018-12-28 | 2019-11-13 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы | Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0107383D0 (en) * | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
| JP2007197369A (ja) * | 2006-01-26 | 2007-08-09 | Sankyo Co Ltd | ベンゾチアジン誘導体 |
| FR2942797B1 (fr) * | 2009-03-03 | 2011-04-29 | Pf Medicament | Derives de benzothiazines, leur preparation et leur application a titre de medicaments |
| KR101134447B1 (ko) * | 2009-11-30 | 2012-04-10 | 에스케이 주식회사 | 아세트아마이드기를 갖는 사이클릭설폰아미드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물 |
| JP2011213685A (ja) * | 2010-04-01 | 2011-10-27 | Kowa Co | ベンゾイミダゾリルピペリジン誘導体を有効成分とする１１β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤 |
| EP2563780B1 (en) * | 2010-04-29 | 2015-05-06 | The University Of Edinburgh | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1 |
| JP5901025B2 (ja) * | 2011-04-19 | 2016-04-06 | 第一三共株式会社 | テトラヒドロチアゼピン誘導体 |
-
2015
- 2015-04-21 FR FR1553574A patent/FR3035326B1/fr not_active Expired - Fee Related
-
2016
- 2016-04-20 BR BR112017021586-1A patent/BR112017021586A2/pt not_active Application Discontinuation
- 2016-04-20 MX MX2017013453A patent/MX2017013453A/es unknown
- 2016-04-20 EP EP16717911.8A patent/EP3285774B1/fr active Active
- 2016-04-20 AU AU2016251601A patent/AU2016251601A1/en not_active Abandoned
- 2016-04-20 RU RU2017137262A patent/RU2017137262A/ru not_active Application Discontinuation
- 2016-04-20 CA CA2981933A patent/CA2981933A1/fr not_active Abandoned
- 2016-04-20 WO PCT/EP2016/058760 patent/WO2016169983A1/fr not_active Ceased
- 2016-04-20 JP JP2017555239A patent/JP2018513175A/ja active Pending
- 2016-04-20 CN CN201680023190.6A patent/CN107530355A/zh active Pending
- 2016-04-20 US US15/568,085 patent/US20180140609A1/en not_active Abandoned
- 2016-04-20 KR KR1020177030299A patent/KR20170139030A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016169983A1 (fr) | 2016-10-27 |
| RU2017137262A3 (enExample) | 2019-09-30 |
| CN107530355A (zh) | 2018-01-02 |
| JP2018513175A (ja) | 2018-05-24 |
| EP3285774B1 (fr) | 2020-01-08 |
| BR112017021586A2 (pt) | 2018-07-03 |
| MX2017013453A (es) | 2017-12-07 |
| US20180140609A1 (en) | 2018-05-24 |
| FR3035326A1 (fr) | 2016-10-28 |
| FR3035326B1 (fr) | 2017-05-12 |
| EP3285774A1 (fr) | 2018-02-28 |
| CA2981933A1 (fr) | 2016-10-27 |
| AU2016251601A1 (en) | 2017-11-30 |
| KR20170139030A (ko) | 2017-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| ZA201707524B (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
| SG10201811185YA (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| PH12018500569B1 (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
| MY187068A (en) | Indole derivatives as dengue viral replication inhibitors | |
| EP3568149C0 (en) | PHARMACEUTICAL COMPOSITION COMPRISING FUSION PROTEINS FOR THE PREVENTION OR TREATMENT OF HEPATITIS, HEPATIC FIBROSIS AND HEPATIC CIRRHOSIS | |
| ZA201901370B (en) | Formulations for oral administration of active agents | |
| HUE067057T2 (hu) | Gyógyszerkészítmény C5-tel kapcsolatos betegség kezelésében vagy megelõzésében történõ alkalmazásra | |
| BR112016024020A8 (pt) | composição farmacêutica | |
| MX2016014696A (es) | Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| RU2017137262A (ru) | Применение (4-гидрокси-2-метил-1,1-диоксид-2н-бензо[е][1,2]тиазин-3-ил)(нафталин-2-ил)метанона для профилактики и/или лечения неалкогольного стеатогепатита | |
| JP2019529569A5 (enExample) | ||
| MD4763B1 (ro) | Compoziţie farmaceutică | |
| JP2018513175A5 (enExample) | ||
| EA201990883A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| EA201692514A1 (ru) | Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением | |
| JP2019518052A5 (enExample) | ||
| EA201692507A1 (ru) | Фармацевтические комбинации софосбувира и рибавирина | |
| ZA201801839B (en) | Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof | |
| ECSP18001655A (es) | Composición de péptidos múltiples | |
| MY185672A (en) | Mono-or di-substituted indole derivatives as dengue viral replication inhibitors | |
| EA201692515A1 (ru) | Новая фармацевтическая композиция на основе софосбувира и рибавирина | |
| EP2924024A3 (en) | Solid forms of lorcaserin hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200120 |